Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1674517 | 1.00 | MAPT (0.58) | MAPTSMN1; SMN2HTTDNM1ADRB2 | |
| SCHEMBL28883157 | 0.83 | MAPT (0.55) | MAPTSMN1; SMN2HTTADRB2ADRB1 | |
| SCHEMBL21843138 | 0.83 | MAPT (0.55) | MAPTSMN1; SMN2HTTDNM1ADRB2 | |
| SCHEMBL14081111 | 0.82 | IDO1 (0.43) | MAPTSMN1; SMN2HTTALDH1A1GAA | |
| SCHEMBL13057591 | 0.82 | ALDH1A1 (0.57) | MAPTSMN1; SMN2HTTALDH1A1LMNA | |
| SCHEMBL168120 | 0.81 | MAPT (0.57) | MAPTSMN1; SMN2HTTDNM1ADRB2 | |
| SCHEMBL182877 | 0.81 | MAPT (0.52) | MAPTSMN1; SMN2HTTDNM1ADRB2 | |
| SCHEMBL7277860 | 0.81 | MAPT (0.68) | MAPTSMN1; SMN2HTTDNM1ADRB2 | |
| SCHEMBL22622594 | 0.80 | MAPT (0.54) | MAPTSMN1; SMN2HTTALDH1A1GAA | |
| SCHEMBL13057582 | 0.80 | ALDH1A1 (0.46) | MAPTSMN1; SMN2ALDH1A1TDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586913-B2 | Processes for the preparation of linezolid using novel intermediates | SYMED LABS LIMITED (IN) | 2017-03-07 | — | — | US | claimed |
| US-20160102064-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2016-04-14 | — | — | US | claimed |
| EP-2989097-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | Symed Labs Limited (IN) | 2016-03-02 | — | — | EP | claimed |
| WO-2014174522-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2014-10-30 | — | — | WO | claimed |
| US-9586913-B2 | Processes for the preparation of linezolid using novel intermediates | SYMED LABS LIMITED (IN) | 2017-03-07 | — | — | US | disclosed |
| US-20160102064-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2016-04-14 | — | — | US | disclosed |
| EP-2989097-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | Symed Labs Limited (IN) | 2016-03-02 | — | — | EP | disclosed |
| WO-2014174522-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102064-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | CYP3A5, SBDS, MLYCD | MAPT 2879/4885SMN1; SMN2 3551/4885HTT 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.